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Abstract: Cu(II) complexes of 1-[4-(3-ethyl-piperidine-2,6-dione)-3-yl]-phenyl-2,4,6-trisubstituted
pyridinium perchlorates, containing alkyl, aryl and combinations of these two types of moieties in their
molecule were synthesized and characterized by elemental analysis, spectroscopy, magnetic,
thermogravimetric and conductimetric measurements. In these complexes, Cu(II) ions are in octahedral
geometry with four water molecules occupying the equatorial coordination sites and the two organic ligands
in deprotonated state the remaining axial ones. The donor atom of these ligands is constituted by the ionized
nitrogen of the glutarimide moiety. The new derivatives possess weak inhibitory activity towards the zinc
enzyme carbonic anhydrase.
Introduction
A large series of biologically active coordination compounds containing heterocyclic sulfonamides
as ligands were reported recently 2-4. Such derivatives behave as potent inhibitors of the ubiquitously
spread zinc enzyme carbonic anhydrase (CA, EC 4.2.1.1) 2a,5 and since ligands such as acetazolamide 1,
methazolamide 2 or ethoxzolamide 3 are widely used pharmacological agents in the treatment of a varie
of disorders, 5,6 presumably, their complexes might lead to the development of novel types of such drugs.2a
In addition to these classical CA inhibitors, complexes were also prepared from positively-charged
sulfonamides of type 4 (developed as isozyme-specific inhibitors for membrane-bound CA isozymes 7) as
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well as saccharin 5 (for which CA inhibitory properties were recently reported8) or diazoxide 6, a
compound possessing a completely different type of biological activity, but a coordination chemistry
similar to that ofcompounds 1-4. 1
All these ligands coordinate transition- or main-group metal ions by means of the sulfonamido
nitrogen atoms, in a monodentate or bidentate fashion (in which case endocyclic atoms such as the
thiadiazolic N-3 or N-4 of acetazolamide 1, or the nitrogen from the benzothiazole ring of ethoxzolamide 3,
participate by interaction with the cations too). 2-4 One of their specific features is the presence of a rather
acidic NH proton in their molecule, with PKa’s in the range 7.0 9.5 in derivatives 1-4 and 6 (saccharin 5
being a much stronger acid, with pKn of 1.3).9 As a consequence, ligands of type 1-6 generally coordinate
metal ions in their deprotonated state. 2-4 In addition to studies previously mentioned by us,2"4 few other
metal complexes were reported containing this type of ligands. A notable exception is constituted by the
Cu(II) complexes of arylsulfonylated amino acids, such as tosylglycine10 or the 4-aminophenylsulfonyl
derivatives of glycine, alanine, valine and glutamic acid. 11
The interesting biological activity of complexes containing such ligands, 2-4,10,11 as well as the
scarcity of literature data in this field, prompted us to extend the studies to related systems, containing a
rather acidic NH group, because of the presence of SO2 or CO moieties in its vicinity.
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Aminoglutethimide (3-(4-aminophenyl)-3-ethylpiperidine-2,6-dione, 7) derivatives, such as the
positively-charged compounds of type $, recently reported, 12 appeared as interesting candidates for several
reasons. Thus, aminoglutethimide is a clinically used dru in the treatment of breast and prostate cancer, 13
adrenocortical carcinoma 14 and Cushing syndrome 15 among others. It inhibits the conversion of
cholesterol to 20--hydroxycholesterol, inhibiting in fact the cytochrome P-450 hydroxylation of this
substrate. 16 In this way the first step of steroidogenesis is inhibited, a fact that explains the efficiency of the
drug in the treatment of tumors sensitive to such hormones. 13"16 On the other hand, the NH proton in
derivatives of type $ is sufticiently acidic (PKa-s in the range 9.0-9.6 12) to allow easy deprotonation and
participation in interactions with metal ions, similarly with derivatives of types 5 and 6 previously
investigated by us. 1,2-4 It is also to expect that such complexes would be biologically active, since the
ligands possess prominent such properties. 12
In this paper I report the preparation and characterization of Cu(II) complexes of positively-
charged derivatives of aminoglutethimide of type $. The new complexes were characterized by elemental
analysis, IR and electronic spectroscopy, as well as magnetic moment measurements, conductimetric and
thermogravimetric data. They were also tested for their ability to inhibit CA, showing weak such properties.
Materials and Methods
IR spectra were obtained KBr pellets, with a Beckmann 4260 instrument, in the range 200 4000
cm1. Electronic spectra were obtained by the diffuse reflectance technique in MgO as reference, with a
Perkin Elmer Lambda 17 apparatus. Conductimetric measurements were done in DMF solutions, at 25C
(concentrations of 1 mM of complex) with a Fisher conductimeter. Magnetic susceptibility measurements
were done at room temperature by Faraday’s method, using CoHg(NCS)4 as standard. Elemental analyses
were done by combustion for C,H,N with an automated Carlo Erba analyzer, and gravimetrically for the
metal ion, and were + 0.5% of the theoretical values. Thermogravimetric measurements were done in air, at
a heating rate of 10C/min., with a Perkin Elmer 3600 thermobalance.
Aminoglutethimide 7 (pure L stereoisomer) used in the syntheses was from Sigma. Pyrylium
perchlorates used to prepare derivatives 8 (by reaction with aminoglutethimide) were synthesized by
literature procedures, by bisacylation of olefins or their precursors, as originally described by Nenitzescu
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and Balaban17, from commercially available raw materials. Compounds 8 were synthesized as reported
previously, 12 from 7 and trisubstituted pyrylium salts in alcohol, by the general method involved in
reaction of such reagents with N-nucleophiles. 18 Copper(II) perchlorate was from Aldrich and was used
without additional purification. Bovine CA II and human CA I were from Sigma Chemical Co. Inhibitors
Maren’s micromethod, in the conditions of the E-I (enzyme-inhibitor) technique, at 0C in were assayed bYl9 veronal buffer. ICso values represent the molarity of inhibitor producing a 50% decrease of CA specific
activity for the CO2 hydration reaction.
Synthesis of coordination compounds 9a-f
An amount of 20 mMoles of pyridinium perchlorate 8a-f was suspended in 50 mL of ethanol and 20
mMoles ofNaOH dissolved in 10 mL water were added. This solution was treated with an aqueous solution
obtained by dissolving 10 mMoles of Cu(II) perchlorate in 10 mL of water, under intense stirring. The
reaction mixture was stirred at room temperature for hour, complexes 9a-f which precipitated were
filtered and air-dried. Yields were of 75-80%.
Results and Discussion
Compounds 8a-f used in this study were previously re!orted, 12 and were obtained by reaction of
2,4,6-trisubstituted pyrylium salts with aminoglutethimide 7.18 Compounds used in the present study,
shown in Table I together with some selected IR bands (relevant for their complexation behavior), possessed
aliphatic, aromatic and the combination of these two moieties in their molecules, which were chosen in
order to investigate the role of substitution pattern upon properties and biological activity of the obtained
complexes.
Table I: Compounds 8a-f used for the preparation of Cu(II) complexes and some of their selected IR bands.
R1
,,a3 H
ClO4
8 R1 R2 R3 IR Bands a (cm"1)
amide Ib amide IIc amide IIId v (NH)e
a Me Me Me 1690 1520 1295 3060
b i-Pr Me i-Pr 1695 1520 1300 3060
c t-Bu Me t-Bu 1690 1535 1290 3070
d Me Ph Me 1690 1500 1280 3050
e Me Ph Ph 1690 1500 1270 3050
f Ph Ph Ph 1700 1520 1270 3050
a In KBr; b Strong and sharp band; c Medium intensity band; d Weak band; e Weak and broad band.
Complexes 9 were prepared from Cu(II) perchlorate and the sodium salts of 8 (obtained in situ
from 8 and the stoichiometric amount of NaOH), in molar ratios of 1:2. The blue-green complexes obtained
in this way are shown in Table II, together with their elemental analysis and thermogravimetric data (:t0.5
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% of the theoretical values for Cu, C, H, N and water).
Table II: Complexes 9a-f of the type [CuL2(OH2)4](CIO4)2 prepared and their elemental analysis data. L
stands for the deprotonated species of derivatives Sa-f. Moieties R1-R3 in compounds 9a-f are those
originally present in the corresponding derivatives 8.
9 Color M.p. Analysis (calc./found)
(C) %Cu
a ocb %H
b oNb %H2OC
a blue
b blue
c blue
d smaragd
e green
f green
287-9
d 6.3/6.1
26t-3
d 5.9/5 8
228-9 5.8/55
244-6
d 5.9/5.5
271-40 5.6/5.4
288-90 5.3/5.2
50.0/49.8
56.5/56.4
59.4/59.3
58.4/58.1
65.8/65.7
72.4/72.1
5.5/5.2
6.8/6.7
7.3/7.3
5.6/5.5
5 7/5.7
5.7/5.5
5.5/5.4 7.1/6.9
5.3/5.2 6’.8/6.8
5.1/5.1 6.6/6.4
5.2/5.0 6.7/6.3
4.9/4.8 6.3/6.0
4.7/4.5 6.0/6.1
aBy gravimetry; bBy combustion; c By thermogravimetric (TG) analysis; all four water molecules are lost in
a single step, between 160-180C; d With decomposition; compounds 9 were recrystallized from
isopropanol-water (4:1, v/v).
Spectroscopic (IR and electronic), magnetic and conductimetric data of complexes 9a-f are
presented in Table III.
In the IR spectra of the prepared complexes 9, the following modifications were detected, as
compared to the spectra of the corresponding derivatives 8: (i) the absence of v(NH) vibrations, which for
Sa-f appeared at 3050-3070 cm-1; (ii) the shift of the very intense "amide I" band (v(C=O)) with 20-30 cm
-1
towards lower wavenumbers for complexes 9 (Table III) as compared to the corresponding vibrations of
derivatives 8 (Table I); (iii) the other amide bands ("amide II" around 1500-1520 cm"1, and "amide III"
around 1270-1300 cm"1 in the ligands) appear in complexes 9 at almost the same wavenumbers (data not
shown), but they are not so well resolved and have a reduced intensity; (iv) the very intense perchlorate
bands, at 625 and 1100 cm"1, are present in both compounds $ and 9; (v) at wavenumbers under 400 cm-1,
all complexes 9 show low intensity bands at 380 and 290 cm-1, tentatively assigned as due to Cu-O and Cu-
N stretching vibrations.20,21
Table III: Spectroscopic, magnetic and conductimetric data of complexes 9a-f.
IR. Spectra
a ,cm-1 Electronic Spectra b, XeffC Conductimetryd
v(M-L) v(C=O) ,max, (cm’l) (BM) (if2-1.cm2.M-1)
a 290;380 1670 14,300 2.29 287
b 290;380 1670 14,320 2.26 293
c 290;380 1660 14,200 2.30 298
d 290;380 1660 14,400 2.20 275
e 290;380 1670 14,200 2.24 280
f 290;380 1670 14,200 2.25 265
a In KBr;
solution.
b By diffuse reflectance in MgO as standard;
c At room temperature; d In DMF, at 25C, 10
-3 M
The magnetic moment data (at room temperature) of the new complexes around 2.2-2.3 BM are
typical for Cu(II) in octahedral surrounding.20,21 In the diffuse reflectance spectra of these complexes a
very broad and large band, centered at 14,200-14,400 cm"1 was detected, which is probably due to intense
charge-transfer effects occurring with this type of positively-charged ligands, 3,7 so that the specific d-d
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transitions of Cu(II) are not seen. On the other hand, conductimetric measurements in DMF solutions of
complexes 9 show a 1:2 electrolyte type of behavior for all of them, with molar conductibilities around 300
_l.cm2.M.1" 3.1o
From the above data it can be concluded that ligands $ act monodentately, through the ionized
imidic nitrogen, similarly with saccharin 53,4,22 and diazoxide 6,1 for which similar complexes were
reported. Taking into account the presence of four coordinated water molecules in complexes 9, the
structure proposed for the new complexes is shown bellow and is similar to the structure of the saccharin
complex [Cu(sac)2(OH2)4] which was determined by means ofX-ray crystallography. 22
R1
N
t
The prepared complexes as well as the original ligands were tested for their ability to inhibit CA
isozymes I and II by Maren’s micromethod. 19 Inhibition data with compounds $,9 and standard inhibitors
for comparison are presented in Table IV.
Table IV" CA I and II inhibition data, for CO2 hydration, with compounds 1, 5-17, determined by Maren’s
method.
19 For comparison data of a strong (1) and a weak (5) CA inhibitor are also included.
Compound ICo (M)
a
CA CA II
1 0.2
b 0.07
b
5 188 97
c
8a 450 380
8b 420 310
8e 445 340
Sd 390 215
Se 850 540
8t" 970 580
9a 105 68
9b 95 82
9c 90 60
9d 105 45
9e 440 360
9f 485 390
a Molarity of inhibitor producin a 50% decrease ofenzyme specific activity for the CO2 hydration reaction,
at OC;
b From refs.5;
c From ref.
a
From data of Table IV it can be seen that, as expected, derivatives 8,9 behave as weak inhibitors of
both CA isozymes. Still, it is obvious that the substitution pattern of the pyridinium ring strongly influences
biological activity,, as for positively-charged sulfonamides of type 4 possessing the same type of groups in
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their molecules. 7 Thus, derivatives 8 are extremely weak inhibitors for both isozymes, the strongest one
being the 2,6-dimethyl-4-phenyl-pyridinium substituted compound 8d (significant inhibition in the
millimolar range). The Cu(II) complexes 9 behave as much stronger inhibitors, presumably due to a dual
inhibition, as observed for the metal complexes of heterocyclic sulfonamides. 1-4 As expected, complexes 9
inhibit these two isozymes 2 to 6 times stronger as compared to the corresponding compounds $ from which
they are derived. The strongest inhibitor was always the one containing the 4-phenyl-2,6-dimethyl moiety,
followed by the complexes possessing only aliphatic groups at the pyridinium ring. In contrast, the weakest
inhibitors were those possessing more than one aromatic group in that position ($e,f and 9e,f, respectively).
This is probably due to the very bulky nature of the last derivatives and an impaired access within the CA
active site.
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